Journal
CELL METABOLISM
Volume 33, Issue 4, Pages 740-747Publisher
CELL PRESS
DOI: 10.1016/j.cmet.2021.03.014
Keywords
-
Categories
Funding
- Diabetes Canada Clinician-Scientist award
- Boehringer Ingelheim Chair in Beta-cell Preservation, Function and Regeneration at Mount Sinai Hospital
Ask authors/readers for more resources
The discovery and progress of insulin demonstrate the promise and challenge of biochemically modifying the molecule to optimize its therapeutic efficacy. Exogenous insulin therapy, although beneficial, still presents clinical challenges in replicating the complex physiology of endogenous insulin secretion.
The discovery of insulin in 1921 and the progress achieved in the ensuing century highlight the promise and challenge of biochemically modifying the molecule to achieve optimization of its delivery and therapeutic efficacy. Normal endogenous insulin secretion consists of a highly orchestrated physiologic loop wherein multiple metabolic signals trigger the pancreatic beta cells to secrete the precise amount of insulin into the portal system required to maintain euglycemia. Accordingly, in the treatment of diabetes, attempting to replicate this complex physiology with exogenous insulin therapy given subcutaneously presents a clinical challenge. In this context, recombinant DNA-based technology has enabled the development of insulin analogs that have been specifically designed to confer advantageous pharmacodynamic features that can better mimic endogenous insulin secretion. In this review, we discuss the development of the most widely available insulin preparations and provide evidence-based insight into their use in clinical practice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available